Nuts and Bolts – Using PET’s New Imaging Agents
Sponsored by the SNMMI Clinical Trials Network
Regan I. Butterfield Schuchart, BS, CNMT, ARRT(CT), Martinos Center for Biomedical Imaging
John M. Hoffman, MD, University of Utah School of Medicine
Amanda Abbott, CNMT, RT(N)(CT), PET
Farrokh Dehdashti, MD, Washington University, St. Louis
Erik Mittra, MD, PhD, Oregon Health & Science University
Val J. Lowe, MD, Mayo Clinic, Rochester
The year 2020 will be one for the history books thanks to Covid-19 but there were some bright spots for molecular imaging, namely 3 new imaging agents. This nuts and bolts session will review three newly approved PET imaging agents – 18F-FES, 18F-flortaucipir, and 64Cu-DOTATATE. 18F-FES is approved for the detection of estrogen receptor positive lesions in metastatic or recurrent breast cancer. 18F-flortaucipir is indicated for PET imaging of the brain to estimate tau burden in adults with cognitive impairment being evaluated for Alzheimer’s Disease. 64Cu-DOTATATE is the first product approved with the 64Cu isotope and is indicated for localization of NETs in adults. The session will review the agents’ availability, who to image, how to use, and when to use.
1. List the indications for 18F-FES, 18F -flortaucipir, and 64Cu-DOTATATE.
2. Choose appropriate patients for 18F-FES, 18F-flortaucipir, and 64Cu-DOTATATE imaging.
3. Discuss how and where to acquire 18F-FES, 18F-flortaucipir, and 64Cu-DOTATATE doses.
CE Credit applications for physicians, pharmacists, physicists and technologists are pending. Check back for updates regarding CE Credit status.